Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer

计划入组 60 人 · 首次发布于 2025 年 7 月 15 日

A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors

计划入组 191 人 · 首次发布于 2026 年 3 月 10 日

Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells for Gastric/Gastroesophageal Junction Adenocarcinoma

计划入组 12 人 · 首次发布于 2024 年 4 月 8 日

TAC-Claudin 18.2

anti-Claudin-18.2 monoclonal antibody

anti-claudin 18.2 CAR T-cell therapy

GOBBI CLAUDIO

Italy

Claudia Spies

Germany

LABORATOIRE CHAUVIN

France

Vyloy Leads Claudin 18.2 Targeted Therapy Revolution with 60+ Drug Candidates in Pipeline

Claudin 18.2-Targeted Therapies Show Promise in Gastric and Other Cancers

Triumvira Immunologics Presents Promising Phase 1 Data for TAC101-CLDN18.2 in Solid Tumors